Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06804902Not ApplicableWithdrawn

MaCRA Part B in Côte d'Ivoire

Role: collaborator

NCT06805110Not ApplicableWithdrawn

MaCRA Part B in Nigeria

Role: collaborator

NCT04864444Not ApplicableCompleted

Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

Role: collaborator

NCT04241705Not ApplicableUnknown

Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia

Role: collaborator

All 4 trials loaded